Summary

  • AtaiBeckley stockholders are scheduled to vote on Lilly’s acquisition at 11:00 a.m. ET on 8 September; the affirmative threshold is a majority of all voting power outstanding, not merely votes cast.
  • The Australian Competition and Consumer Commission’s 14-day wait is scheduled to expire at 10:00 a.m. ET on 10 September, 47 hours after the meeting begins. That date is a regulatory receipt, not an automatic closing.
  • Closing would exchange each eligible share for US$6.75 cash and one non-tradable CVR with separate four-, five- and seven-year milestone expirations; the contingent US$2.50 maximum is neither guaranteed nor payable at closing.

The acquisition now has a compact public timetable. AtaiBeckley’s definitive proxy schedules a virtual stockholder meeting for 11:00 a.m. Eastern Time on 8 September. A later Form 8-K says the Australian Competition and Consumer Commission determined that the merger may be consummated after a 14-calendar-day waiting period scheduled to expire at 10:00 a.m. Eastern Time on 10 September.

Those two timestamps are 47 hours apart. The interval is easy to mistake for a countdown to completion. It is better read as a handoff between different authorities.

A vote authorizes the contract; it does not close it

AtaiBeckley reported 370,864,669 shares entitled to vote on the 7 August record date. Adoption requires the affirmative vote of holders of a majority of the voting power outstanding. A failure to vote and a broker’s inability to act without instructions therefore work against adoption rather than disappearing from the denominator.

The meeting is one corporate-control gate. It does not certify the regulatory record, satisfy every covenant or file the Delaware certificate of merger. The July transaction filing lists other conditions, including regulatory approvals, accuracy of representations, compliance with covenants, absence of a continuing company material adverse effect and absence of a government proceeding seeking to block or materially impair the deal.

The regulatory receipts are also narrower than “cleared.” The US Hart-Scott-Rodino waiting period expired at 11:59 p.m. on 28 August. The UK Competition and Markets Authority said on 21 August that it had, at that time, no further questions. Australia imposed the further 14-day clock. Each statement describes a jurisdiction and a procedural state. None says every condition has been met.

Under the merger agreement, once the conditions that can be met before closing are satisfied or waived, closing is to occur as soon as practicable and no later than the first business day afterward, unless the parties agree another date. That clause still does not make 10 September a promised closing date.

US$6.75 and US$2.50 live on different ledgers

If the merger reaches effective time, each eligible AtaiBeckley share is cancelled in exchange for US$6.75 in cash, without interest and less applicable withholding, plus one contingent value right. The joint announcement filed with the SEC described the upfront equity value as about US$2.8 billion and the potential aggregate CVR value as about US$1.0 billion. It also said there can be no assurance that any CVR payment will be made.

The word “plus” can obscure the architecture. The US$6.75 is consideration at closing. The maximum US$2.50 is divided among three later tests:

  • up to US$1.00 if the first patient is dosed in a Phase 3 VLS-01 trial for a qualifying indication before the fourth anniversary of closing;
  • up to US$0.50 if BPL-003 obtains its first US regulatory approval for a qualifying indication and the DEA reschedules the approved product out of Schedule I before the fifth anniversary;
  • up to US$1.00 if VLS-01 obtains its first US regulatory approval for a qualifying indication and the DEA reschedules approved DMT out of Schedule I before the seventh anniversary.

The deadlines are anchored to closing. A delayed closing shortens no stated post-closing period before it begins; it moves the calendar dates on which all three periods expire.

Even a met milestone need not produce the full headline amount. The CVR agreement permits a milestone offset based on half of certain payments for intellectual property considered necessary for the relevant product, allocated across outstanding CVRs. “Up to” is doing contractual work.

Former owners become holders of an illiquid contract

At closing, AtaiBeckley ceases to be publicly traded and former stockholders lose their equity rights. The CVR does not preserve them. It is a contractual right only: not certificated, not registered with the SEC, not listed for trading and not transferable except in limited circumstances. It carries no vote, dividend or ownership interest, and no interest accrues while a holder waits.

Lilly must use commercially reasonable efforts toward the specified milestones, subject to the detailed terms. But the contract expressly says that standard does not guarantee a milestone or require simultaneous pursuit of multiple indications for one product. Its indication exclusions also matter. The duty is bounded conduct, not promised success.

Enforcement is collective in most cases. Apart from a finally determined payment that remains unpaid, the rights agent or holders of at least 25% of outstanding CVRs control proceedings on behalf of all holders. A small holder can observe the clock but does not generally hold an individual development veto or litigation lever.

The deal therefore changes more than ownership. It moves AtaiBeckley’s drug programmes into Lilly’s portfolio while moving the seller’s former owners from a liquid equity claim to fixed cash plus a long, illiquid and conditional contract. The September gates decide whether that conversion can begin. They do not decide what the contract will ultimately pay.

Sources